VerImmune, a venture-backed biotechnology company developing a groundbreaking Virus-inspired Particle (ViP™) platform technology, announced the successful first closing of $4.5 million in its Pre-Series A financing round.

The financing was led by Beiley Biofund, an early-stage venture capital firm focused on cutting-edge technologies that address high unmet medical needs. New investors, including Dr. John Ballantyne, PhD, co-founder and former CSO at Aldevron, participated in the round, alongside returning investors Proxima Ventures, Mana Ventures, Gaingels, and others.